Holen Sie sich die Stockscreener-App
309.32
0.08%
-0.25
Vorhandelsmarkt:
309.30
-0.02
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ELV?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$309.57
Offen:
$313
24-Stunden-Volumen:
2.51M
Relative Volume:
1.08
Marktkapitalisierung:
$69.65B
Einnahmen:
$189.25B
Nettoeinkommen (Verlust:
$5.35B
KGV:
13.16
EPS:
23.5
Netto-Cashflow:
$5.34B
1W Leistung:
+6.37%
1M Leistung:
+11.63%
6M Leistung:
-19.13%
1J Leistung:
-43.11%
1-Tages-Spanne:
$309.23
$316.59
1-Wochen-Bereich:
$289.72
$316.59
52-Wochen-Spanne:
$273.71
$567.26
Elevance Health Inc Stock (ELV) Company Profile
Firmenname
Elevance Health Inc
Sektor
Branche
Telefon
(800) 331-1476
Adresse
220 VIRGINIA AVENUE, INDIANAPOLIS
Vergleichen Sie ELV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELV
Elevance Health Inc
|
309.32 | 69.71B | 189.25B | 5.35B | 5.34B | 23.50 |
|
UNH
Unitedhealth Group Inc
|
308.49 | 275.33B | 422.82B | 22.09B | 25.27B | 23.08 |
|
CVS
Cvs Health Corp
|
70.17 | 87.01B | 386.46B | 4.49B | 4.78B | 3.58 |
|
CI
Cigna Group
|
298.32 | 79.24B | 261.22B | 5.40B | 3.94B | 18.32 |
|
HUM
Humana Inc
|
287.19 | 34.44B | 123.11B | 1.58B | 2.44B | 13.03 |
Elevance Health Inc Stock (ELV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Herabstufung | Argus | Buy → Hold |
| 2025-07-18 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-15 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-03-17 | Hochstufung | Argus | Hold → Buy |
| 2025-01-22 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-10-18 | Herabstufung | Argus | Buy → Hold |
| 2024-07-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-06-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2023-07-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-28 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-09-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
Alle ansehen
Elevance Health Inc Aktie (ELV) Neueste Nachrichten
Buffett's Shot in the Arm Sends UnitedHealth Soaring Against the Odds - The Globe and Mail
Elevance Health and National Association of Community Health Centers Partnership Integrates Food as Medicine With Primary Care - Yahoo Finance
Elevance Health Strategies Highlight Financial Optimism Amidst Market Challenges - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Heatmap analysis for Elevance Health Inc. and competitorsEarnings Risk Report & Fast Momentum Entry Tips - Newser
Elevance Health Inc. stock volume spike explainedWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion - MSN
Northern Light Health Ends Contract Negotiations with Anthem - SSBCrack
Can Elevance Health Inc. expand its profit marginsJuly 2025 Review & Accurate Buy Signal Alerts - thegnnews.com
Northern Light Health ending contract with Anthem - WPFO
Elevance Health shares rise 5.10% intraday after Berkshire Hathaway's investment in UnitedHealth boosts health insurers. - AInvest
Wells Fargo Downgrades Elevance Health to Overweight with PT of $330. - AInvest
Elevance Health Inc. Price Holds Above Key Fib Level2025 EndofYear Setup & Advanced Technical Signal Analysis - newsyoung.net
Elevance Health shares rise 4.25% premarket after Wells Fargo adjusted price target and rate-cut expectations. - AInvest
Wells Fargo Adjusts Price Target on Elevance Health to $330 From $400, Maintains Overweight Rating - MarketScreener
Elevance Health Soars 5.1% on Bullish Sentiment - AInvest
Signal strength of Elevance Health Inc. stock in tech scannersJuly 2025 Rallies & Detailed Earnings Play Strategies - Newser
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline - MSN
Elevance Health, Inc. (ELV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Raising Our Uncertainty Ratings on Cigna and Elevance on Medical Utilization and Regulatory Concerns - Morningstar
Uncertainty Rising at Elevance Primarily on Challenges in Medicaid and Individual Exchanges - Morningstar
When 90% Isn't An A+: Elevance's Cost Crunch And Carelon's Cushion - Barchart.com
Anthem Blue Cross Commercial and Exchange Health Plans Awarded NCQA Health Equity Accreditation in California - Business Wire
Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy’ Rating With $342 PT - MSN
Elevance Health Q2 2025 Results: Mizuho Maintains 'Buy' Rating with $342 PT - AInvest
Barrow, Hanley, Mewhinney & Strauss Reduces Stake in Elevance Health Inc by 54.26% - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
When a Healthcare Giant Gets Sick: Elevance Health’s 20% YTD Decline - InsuranceNewsNet
Is Elevance Health Inc. a turnaround storyDouble in 10 Days Stock Ideas - thegnnews.com
The Power of Personalized Care During Pregnancy - www.elevancehealth.com
Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Investors to Inquire about Securities Investigation - ACCESS Newswire
Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral - MSN
Mizuho Securities Maintains Buy Rating on Elevance Health with $342 Price Target - AInvest
Elevance Health (ELV) Nosedives 12% on Disappointing Q2 - MSN
UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects - Insider Monkey
Baird Lowers Elevance Health Price Target to $297, Maintains Neutral Rating. - AInvest
Elevance Health, Inc. (NYSE:ELV) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Iowa House panel dismisses ethics complaint over lobbying on PBM bill - The Des Moines Register
Meta Platforms and Elevance Health have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bear of the Day: Elevance Health (ELV) - The Globe and Mail
Bear Of The Day: Elevance Health (ELV) - Barchart.com
Is it the right time to buy Elevance Health Inc. stockFree Stock Market Trend Analysis - Jammu Links News
When is Elevance Health Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
How strong is Elevance Health Inc. company’s balance sheetCapitalize on market opportunities with confidence - Jammu Links News
Is Elevance Health Inc. stock overvalued or undervaluedFree Risk Assessment Services - Jammu Links News
Should I hold or sell Elevance Health Inc. stock in 2025Proven strategies for superior portfolio growth - Jammu Links News
What are Elevance Health Inc. company’s key revenue driversAchieve consistent double-digit growth - Jammu Links News
Why is Elevance Health Inc. stock attracting strong analyst attentionInvest confidently with real-time data - Jammu Links News
What are analysts’ price targets for Elevance Health Inc. in the next 12 monthsUnlock daily market insights for better decisions - Jammu Links News
Insider Activity at Elevance Health: A Tale of Confidence and Cautious Diversification - AInvest
Elevance Health Insiders Sell US$6.7m Of Stock, Possibly Signalling Caution - Yahoo Finance
Finanzdaten der Elevance Health Inc-Aktie (ELV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):